More recently, Spahis et al. [113] compared children with NAFLD with different degrees of severity in response to n-3 LCPUFA supplementation (2 g/day for 1 year) finding important reductions of the hepatic steatosis, fatty liver index, hepatic enzyme activities (ALT and ALT/AST ratio), lipid profile, oxidative markers and carotid intima media thickness, while enhancing circulating adiponectin in the n-3 LCPUFA group compared to the placebo. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.